Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
Clinical trial NCT03065023 · TERMINATED
Trial details
- NCT number
- NCT03065023
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-25
- Primary completion
- 2018-05-18
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.